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Reversible protein ubiquitination is emerging as a key process for maintaining cell homeostasis, and the enzymes
that participate in this process, in particular E3 ubiquitin ligases and deubiquitinases (DUBs), are increasingly being
regarded as candidates for drug discovery. Human DUBs are a group of approximately 100 proteins, whose cellular
functions and regulatory mechanisms remain, with some exceptions, poorly characterized. One of the best-
characterized human DUBs is ubiquitin-specific protease 1 (USP1), which plays an important role in the cellular
response to DNA damage. USP1 levels, localization and activity are modulated through several mechanisms,
including protein-protein interactions, autocleavage/degradation and phosphorylation, ensuring that USP1 function
is carried out in a properly regulated spatio-temporal manner. Importantly, USP1 expression is deregulated in
certain types of human cancer, suggesting that USP1 could represent a valid target in cancer therapy. This view has
gained recent support with the finding that USP1 inhibition may contribute to revert cisplatin resistance in an
in vitro model of non-small cell lung cancer (NSCLC). Here, we describe the current knowledge on the cellular
functions and regulatory mechanisms of USP1. We also summarize USP1 alterations found in cancer, combining
data from the literature and public databases with our own data. Finally, we discuss the emerging potential of
USP1 as a target, integrating published data with our novel findings on the effects of the USP1 inhibitor pimozide
in combination with cisplatin in NSCLC cells.
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Ubiquitin is a 76 amino acid long peptide that can be
covalently attached to proteins to modulate their stabil-
ity, localization or function. Initially identified as a “de-
struction tag” leading to the degradation of the modified
protein in the proteasome [1], it became later evident
that ubiquitin conjugation also causes a variety of non-
degradative changes in protein localization or function
[2]. Nowadays, ubiquitination is recognized as a key
player in the regulation of a plethora of cellular func-
tions, and its importance for cellular homeostasis is be-
coming increasingly clear.
The conjugation of ubiquitin to a target protein is a
multistep process involving the sequential action of a* Correspondence: josean.rodriguez@ehu.es
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distribution, and reproduction in any mediumubiquitin activating enzyme (E1), a ubiquitin-conjugating
enzyme (E2), and a ubiquitin protein-ligase (E3). E3 ligases
catalyze the final transfer of ubiquitin to a lysine residue
in the target protein, and are largely responsible for the
substrate-specificity of the reaction [3]. In some cases, a
target protein is modified at one or more lysine residues
by the addition of a single ubiquitin molecule (monou-
biquitinated). In other cases, the target is decorated
with a chain of ubiquitin subunits (polyubiquitinated),
linked through one of ubiquitin lysine residues. Since
there are seven lysines in the ubiquitin sequence (Lys6,
Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63),
polyubiquitin chains of different length and topology
can be formed [4]. In addition to chains involving
internal lysine residues, polyubiquitin chains with a lin-
ear topology can also be formed by conjugating mul-
tiple ubiquitin subunits through their amino-terminal
methionine (Met1) residues, a process catalyzed by aed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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quitin chain assembly complex (LUBAC) [5].
The ubiquitin tags can mediate non-covalent interac-
tions of the ubiquitinated substrate with other proteins
bearing different types of ubiquitin-binding motifs. The
type of ubiquitin tag and the resulting interactions deter-
mine the fate of the substrate [6]. The best-characterized
ubiquitin chains are those involving lysine residues
Lys48 and Lys63. Lys48 polyubiquitination usually leads
to the proteasomal degradation of the substrate. In con-
trast, monoubiquitination and Lys63 polyubiquitination
generally lead to proteasome-independent changes in
the localization, in protein-protein interactions, and in
activity of the modified protein [7]. The outcome of
protein polyubiquitination with chains involving ubiqui-
tin lysines other than Lys48 and Lys63, or the linear
polyubiquitination involving Met1, is less well under-
stood, and is the focus of intense research [8].
Ubiquitination is a very common posttranslational modi-
fication. Global proteomics analyses have revealed that
thousands of cellular proteins are ubiquitinated [9]. Similar
to other posttranslational modifications, ubiquitination is a
reversible process, and there is a family of enzymes, termed
deubiquitinases (DUBs), that act on ubiquitinated sub-
strates to catalyze the removal of ubiquitin moieties [10].
In vitro studies have shown that, while some DUBs prefer-
entially cleave specific ubiquitin linkages [11,12], others
show a notable promiscuity with respect to the type of
ubiquitin linkage they can hydrolyze [13]. Importantly, a
DUB that specifically cleaves linear ubiquitin chains has re-
cently been identified [14,15].
Thus, it is the balance between the opposing actions
of specific E3 ligases and DUBs which ultimately deter-
mines the ubiquitination status of a given target, render-
ing protein ubiquitination a versatile and dynamic
posttranslational modification. The list of cellular pro-
cesses where ubiquitination plays a regulatory role is
continuously expanding, and includes gene expression
[16], cell cycle progression [17], apoptosis [18], DNA re-
pair [19] and cell motility [20], among others. Many of
these ubiquitination-regulated processes are essential
for maintaining cellular homeostasis, and their alter-
ation contributes to tumor development. The import-
ance of ubiquitination in cancer-related aspects of cell
function, and the clinical success of the proteasome in-
hibitor bortezomib in the treatment of multiple myeloma
[21] have spurred the interest in the proteins that partici-
pate in the processes of ubiquitination/deubiquitination as
potential targets for anticancer therapy [22,23]. In this
regard, several inhibitors of E3 ligases are currently
undergoing clinical trials, as described in detail in recent
reviews [23-25]. On the other hand, although a number of
DUB inhibitors are being tested in a preclinical setting,
the development of DUB-targeted agents is less advanced.This may be due in part to the fact that basic knowledge
on DUBs has lagged behind that on E3 ligases. Neverthe-
less, there has been substantial progress in our under-
standing of the function and regulation of a subset of
DUBs over the last years, and several members of this
family are now being actively explored as potential anti-
cancer targets [23,26].
One of the best-characterized DUBs is USP1 (ubiqui-
tin-specific protease 1), which plays an important role in
the regulation of DNA repair processes. In this article,
we first present a brief overview of the function of hu-
man DUBs, emphasizing their increasingly recognized
potential as targets in cancer treatment. Then, we focus
our attention on USP1, reviewing our current knowledge
on the function and regulation of this DUB. Finally, we
summarize the alterations of USP1 found in human tu-
mors, and discuss novel findings regarding the potential
of this enzyme as a target in the treatment of non-small
cell lung cancer (NSCLC), including novel data that ex-
tend previously reported findings.
Potential of human DUBs as novel targets in cancer
therapy
The human genome contains around 100 genes encoding
for deubiquitinases. Human DUBs can be classified into
five different families. Most DUBs are cysteine proteases
belonging to one of four families, termed ubiquitin-
specific proteases (USPs), ubiquitin carboxy-terminal hy-
drolases (UCHs), ovarian tumor proteases (OTUs), and
Josephins or Machado-Joseph domain (MJD) proteases. A
fifth DUB family, termed JAMM/MPN domain-associated
metallopeptidases (JAMMs) comprises enzymes with zinc
metalloprotease activity [27].
By antagonizing the activity of E3 ligases, DUBs can
rescue a ubiquitinated protein from proteasomal degrad-
ation, or alter its fate in a more subtle way by editing the
length and topology of its ubiquitin tag [28]. DUB
activity modulates the ubiquitination state of many cel-
lular proteins, and thus contributes to regulate their
levels, activity and localization. Besides these regulatory
functions, several DUBs also play a housekeeping func-
tion in the maintenance of the cellular pool of free
ubiquitin. For example, proteasome-associated DUBs,
such as UCHL5, USP14 and POH1, help recycling the
ubiquitin chains from proteins before their proteasomal
degradation [26].
As comprehensively discussed in recent review articles
[29-31], there is mounting evidence supporting the view
that human DUBs play an important role in cancer de-
velopment. Several DUBs involved in cancer-related cel-
lular processes are summarized in Table 1. At least six
different DUBs (USP2a, USP4, USP7/HAUSP, USP10,
USP29 and USP42) contribute to regulate the crucial
tumor suppressor protein p53 [29,32]. On the other hand,
Table 1 Involvement of selected DUBs in the regulation
of cancer-related signalling pathways and cellular
processes
DUB Signalling pathway/Process Substrate
USP2a Fas and p53 FAS, MDM2, MDMX
Mitotic progression Aurora A
NF-κB RIP1, TRAF2, TRAF6
Cell cycle Cyclin A1
USP4 Wnt TCF4
p53 ARF-BP1
NF-κB TAK1, TRAF2, TRAF6, RIP1




USP7 p53 p53, MDM2, MDMX
Akt FOXO4, PTEN




USP8/Ubpy Endosomal sorting EGFR
Wg/Wnt Frizzled
Hedgehog Smoothened
AMSH Endosomal sorting EGFR
Cezanne NF-κB TRAF6, RIP1
CYLD NF-κB TRAF2, TRAF6, TRAF7,
TAK1, RIP1
Table shows several human DUBs involved in the regulation of different
signalling pathways/processes, as well as their reported substrates. An
extended version of this Table, including references, is provided as Additional
file 1: Table S1.
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such as those mediated by EGFR, NFκB, TGFβ or WNT,
is, at least in part, controlled by DUBs [30,33]. Regulation
of these pathways often involves the concerted action of
several DUBs. As an example, EGFR-mediated signal
transduction can be regulated at the level of receptor
endocytosis, trafficking and degradation by the DUBs
USP8/Ubpy, AMSH, USP2a and Cezanne [34-36], but also
at a more downstream level by DUBs like USP7/HAUSP
or CYLD that modulate the ubiquitination of PTEN or
Akt, respectively [37,38]. DUBs may also contribute to the
crosstalk between different pathways, as illustrated by
USP4, which is regulated by Akt-mediated phosphoryl-
ation and deubiquitinates the TGFβ-I receptor [39]. In
addition to signal transduction, DUBs also regulate funda-
mental cellular processes frequently disrupted in cancer,
such as cell cycle progression, apoptosis, or the response
to DNA damage [29,31,40]. Importantly, altered expres-
sion of DUBs seems to be a recurrent finding in different
types of human cancer [30].As a result of all these findings, human DUBs are in-
creasingly regarded a potential targets in cancer therapy
[24,41]. Several DUB-targeting compounds have been
identified, and are currently being tested in a preclinical
setting. Some of these compounds, such as PR-619 and
WP1130, inhibit a large subset of DUBs, whereas others,
such as b-AP15, exhibit a higher target specificity. PR-619
is a reversible, cell permeable pan-DUB inhibitor that tar-
gets a wide range of DUBs, but shows selectivity toward
DUBs over other proteases, such as calpain 1, or cathep-
sins [42]. WP1130, on the other hand, inhibits at least five
DUBs: USP5, UCH-L1, USP9X, USP14, and UCH37, and
induces the cellular accumulation of polyubiquitinated
proteins [43]. Finally, b-AP15 specifically inhibits two
proteasome-associated DUBs: UCH-L5 and USP14, and
thus blocks proteasome function leading to the accumula-
tion of polyubiquitin in treated cells [44]. PR-619 is being
developed mainly as a research tool. With regard to the
therapeutic potential of WP1130 and b-AP15, although
both compounds have been shown to promote tumor cell
apoptosis in preclinical models [43,44], DUB inhibitors
with narrower target specificity, such as b-AP15, might be
more easily amenable to clinical development, since DUB
inhibitors with broader specificity, such as WP1130, may
be more prone to cause unwanted side effects that are dif-
ficult to predict.
The interest in DUBs as therapeutic targets is further
reflected by the impressive number of ongoing efforts to
develop and characterize novel DUB inhibitors using in-
novative strategies, such as chemical synthesis of ubiqui-
tin bioconjugates [45] or phage display-based selection
of ubiquitin mutants with enhanced affinity for specific
DUBs [46].
An extremely interesting subset of DUBs from the point
of view of anticancer therapy are those that function in
the cellular response to DNA damage. Many conventional
chemotherapeutic drugs, such as cisplatin, are genotoxic
agents that may elicit a DNA damage response (DDR). De-
pending on the type of DNA damage, different DDR path-
ways are activated that may, in some cases, render cancer
cells resistant to chemotherapy [47,48]. DDR pathways are
complex multistep processes involving molecular mecha-
nisms for damage recognition, checkpoint activation, sig-
naling, and recruitment of the DNA repair machinery to
the site of the lesion. It is becoming increasingly clear that
the DDR is critically regulated by ubiquitination and
deubiquitination, and thus, the concept has evolved that
targeting the enzymes that play a role in these processes,
including DUBs [19,49-51], might be an approach to
overcome resistance to conventional therapy [40]. It has
been suggested, for example, that inhibition of USP7, a
DUB that functions in the G2/M checkpoint triggered by
DNA damage, might improve treatment efficiency when
used in combination with a genotoxic agent [42].
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represents a prominent example of a DUB that partici-
pates in DDR pathways and may constitute a promising
anticancer target.
Cellular functions and substrates of USP1
The USP1 gene, cloned in 1998, encodes a 785 amino
acid protein with a predicted molecular weight of 88.2
KDa [52]. USP1 bears the conserved USP domain that
characterizes this DUB family, with an amino-terminal
Cys box motif and a carboxy-terminal His box motif that
contain the catalytic residues (Cys90, His593 and Asp751)
[52-54] (Figure 1A).
The best-characterized function of USP1 is as a regula-
tor of several important steps in the DNA damage re-
sponse, mainly in the Fanconi anemia (FA) pathway [55],
and in the process of translesion synthesis (TLS) [56]. In




















Figure 1 USP1 Domain structure and summary of the cellular functio
protein showing the position of its amino-terminal Cys box and carboxy-te
Asp751 are indicated by arrowheads. B. Models illustrating the role of the
In the Fanconi anemia (FA) pathway (upper panel), the FA core complex m
of other proteins that repair DNA interstrand crosslink (ICL) lesions. USP1/U
FANCI. In the process of translesion synthesis (TLS) (middle panel), monoub
bypass DNA lesions, but have lower fidelity than replicative polymerases. U
polymerases by deubiquitinating PCNA. Finally (lower panel), USP1/UAF1 c
osteosarcoma cells by promoting deubiquitination and stability of ID prote
transcription factors.contribute to regulate differentiation in specific cellular
contexts [57]. As detailed below, these functions are car-
ried out by USP1 in a heterodimeric complex with its
cofactor UAF1 (USP1-associated factor 1) [58].
FA is a rare hereditary disorder characterized by con-
genital abnormalities, progressive bone marrow failure,
hypersensitivity to DNA crosslinking agents, genomic in-
stability and increased susceptibility to cancer [59]. Mu-
tations in at least 15 genes have been shown to cause
FA. The products of these genes are active in the DNA re-
pair pathway that corrects insterstrand crosslinks (ICL), a
DNA lesion that causes polymerase stalling. In response
to this type of genomic damage, eight FA proteins assem-
ble in a nuclear complex with ubiquitin E3 ligase activity,
termed the FA core complex, which monoubiquitinates
two other FA proteins, FANCD2 and FANCI, at the site of
the lesion. In turn, monoubiquitinated FANCD2 (ub-
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ns of the USP1/UAF1 complex. A. Shematic representation of USP1
rminal His box domains. The catalytic residues Cys90, His593 and
USP1/UAF1 complex as regulator of three different cellular processes.
onoubiquitinates FANCD2 and FANCI, which mediate the recruitment
AF1 antagonizes the FA core complex deubiquitinating FANCD2 and
iquitinated PCNA recruits specific TLS DNA polymerases that may
SP1/UAF1 may prevent unscheduled recruitment of low fidelity TLS
ontributes to the maintaince of the undifferentiated state of
ins, which, in turn, negatively regulate differentiation-inducing bHLH
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repair proteins that carry out the subsequent steps of ICL
correction (reviewed in [51]). USP1 deubiquitinates both
ub-FANCD2 [55] and ub-FANCI [60], thus reverting
the critical event in the activation of the FA pathway
(Figure 1B, upper panel). USP1-mediated deubiqui-
tination of FANCD2 and FANCI is crucial for the cor-
rect function of the FA pathway, as evidenced by the
observation that USP1 gene knockout in murine models
or DT40 chicken cells recapitulates many phenotypical
aspects of FA, including haematopoietic defects and
hypersensitivity to DNA crosslinking agents [61-64].
A second DNA repair-related process, translesion
synthesis (TLS), is also regulated by USP1, further sup-
porting the crucial role of this DUB in the DNA damage
response. The critical USP1 substrate in TLS is PCNA
(Proliferating Cell Nuclear Antigen) [56]. Following
DNA damage that stalls the progression of the replica-
tion fork, PCNA is monoubiquitinated at lysine 164 by
the Rad18 E3 ligase [65]. Monoubiquitinated PCNA (ub-
PCNA) facilitates the recruitment of specific TLS poly-
merases, which can bypass the lesion [66]. PCNA can
also be monoubiquitinated in the absence of DNA dam-
age by the CRL4Cdt2 E3 ubiquitin ligase complex [67].
TLS polymerases have a lower fidelity than replicative
polymerases, and may thus result in a higher mutagen-
esis rate. By reverting PCNA monoubiquitination [56]
(Figure 1B, middle panel), USP1 contributes to prevent
unscheduled recruitment of TLS polymerases, and may
thus help maintaining genome stability [68].
Finally, USP1 has also been reported to contribute to
the repair of double-strand DNA breaks through
homologous recombination. The molecular mechanism
underlying this function is less clear, but it appears to









Figure 2 Regulatory motifs in USP1 amino acid sequence. Schematic r
motifs that contribute to the regulation of its levels, localization and activit
(orange) that mediates APC/CCdh1-mediated degradation of USP1, and two
nucleus. The UAF1-binding region of USP1 is still a matter of some controv
proposed [73,74]. The position of the diglycine motif (Gly-Gly), which const
the site of Cdk-mediated USP1 phosphorylation, are also indicated.Besides these DNA repair-related functions, USP1 has
been recently reported to deubiquitinate and stabilize
three members of the family of inhibitors of DNA binding
(ID) proteins, namely ID1, ID2 and ID3 [57] (Figure 1B,
lower panel). ID proteins are expressed during develop-
ment in several undifferentiated and proliferating cells
[69]. They are negative regulators of basic helix-loop-helix
(bHLH) type transcription factors, which bind to DNA
and promote the differentiation of various cell types [70].
By deubiquitinating ID proteins, USP1 contributes to pre-
vent bHLH-mediated differentiation, and thus maintain
stem-cell characteristics in osteosarcoma cells [57].
Regulation of USP1 function
Several mechanisms that regulate the expression levels
of USP1, its catalytic activity, and its access to substrates
have been identified. These mechanisms ensure that
USP1 function is carried out in a properly controlled
spatio-temporal manner, and include cell cycle-regulated
expression, protein-protein interactions, autocleavage/
degradation and phosphorylation.
Transcription of the USP1 gene is regulated in a cell
cycle-dependent manner. USP1 mRNA levels remain low
during G1 phase, and reach a peak during S phase [55].
The cell cycle-dependent expression of USP1 is also regu-
lated at the protein level by proteasomal degradation. In
this regard, the USP1 region 295-342 (Figure 2) consti-
tutes a destruction motif (degron) that is required for
Anaphase Promoting Complex/CyclosomeCdh1 (APC/
CCdh1)-dependent degradation of USP1 during G1 [71],
which appears to be further modulated by calpains [72].
Arguably, the most critical event in the regulation of
USP1 deubiquitinase activity is its interaction with UAF1
[58]. UAF1 is a WD40-repeat containing protein that
also binds to and regulates two other DUBs, USP12 and
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epresentation of USP1 protein showing the position of sequence
y. These regulatory motifs include a destruction box or “degron”
NLSs (blue) that mediate import of the USP1/UAF1 complex into the
ersy. As indicated within the box, two different motifs have been
itutes the site of USP1 autocleavage, and the residue Ser313, which is
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enzymatic activity of USP1 alone is very low, and is
dramatically increased upon binding to UAF1 [58].
Although the molecular basis for UAF1-mediated USP1
activation remains to be fully understood, recent in vitro
analyses using artificial substrates support an allosteric
mechanism, involving UAF1-induced conformational
changes in the USP1 active site [53]. Besides increasing
its catalytic activity, UAF1 also stabilizes USP1 [58], and






















































































Figure 3 USP1 gene mutations and altered USP1 mRNA expression in
the position of 13 lung cancer-associated USP1 mutations reported to date
are indicated using the one-letter code. B. Relative USP1 mRNA expression
normal tissue from four NSCLC patients (represented by different symbols)
isolated using Trizol (Invitrogen), and complementary DNA (cDNA) was syn
Scientific). Quantitative real-time PCR (qRT-PCR) was performed using the T
manufacturer’s instructions on an ABI Prism 7500 instrument. Assay-on-Dem
used to specifically amplify USP1 (Hs00163427_m1) and Human GAPD (GA
expression of USP1 mRNA normalized to GAPDH internal control in norma
pooled samples of the three different NSCLC histological subtypes (grey ba
carcinoma). Each pooled sample included laser-microdissected specimens
analysis was carried out as described above. Graph bars show mean ± SEM
(***P < 0.001). D. Relative USP1 mRNA expression normalized to GAPDH in
lung tissue mRNA samples. qRT-PCR analysis was carried out as described a
method using the “normal” value as a reference. Graph bars show mean ±Reaching these nuclear substrates first requires nuclear
import of the USP1/UAF1 complex, which is mediated
by two nuclear localization signals (NLSs) in USP1
(Figure 2) [73]. Then, a SUMO-like domain (SLD2) in
UAF1 mediates the precise targeting of the complex to
ub-FANCD2 (through direct binding to FANCI) [76]
and ub-PCNA (through direct binding to the PCNA
partner ATAD5/ELG1) [77]. Thus, targeting of USP1/
UAF1 to FANCD2 and PCNA can be regarded as a two-




















































lung cancer. A. Shematic representation of USP1 protein showing
(5 April 2013) in the COSMIC mutation database. Amino acid changes
normalized to GAPDH in paired samples of tumor tissue and adjacent
, showing higher USP1 expression in tumor tissue. Total RNA was
thesized using the Dynamo cDNA synthesis kit for qRT-PCR (Thermo
aqMan Universal Master Mix (Applied Biosystems) according to the
and Gene expression primers and probes (Applied Biosystems) were
PDH) Endogenous Control (4326317E). C. Graph comparing the relative
l lung tissue (white bar; four individual samples) with the expression in
r; adenocarcinoma, squamous cell carcinoma and large cell
from five different patients, as described previously [88]. qRT-PCR
. USP1 was significantly overexpressed in the pooled tumor samples
20 different NSCLC cell lines compared to the average of four normal
bove. The relative mRNA levels were determined with the ΔΔCt
SD of two replicates.
Table 2 USP1 over/underexpression in several cancer
tissue types
Cancer type Overexpressed Underexpressed
Sarcoma 11/15 (73%) 0/15 (0%)
Melanoma 4/6 (67%) 1/6 (17%)
Gastric cancer 5/8 (63%) 0/8 (0%)
Cervical cancer 3/5 (60%) 0/5 (0%)
Brain and CNS cancer 10/20 (50%) 1/20 (5%)
Liver cancer 3/10 (30%) 0/10 (0%)
Other cancer 8/27 (30%) 6/27 (22%)
Lung cancer 4/16 (25%) 0/16 (0%)
Bladder cancer 2/9 (22%) 0/9 (0%)
Myeloma 1/5 (20%) 0/5 (0%)
Colorectal cancer 5/26 (19%) 0/26 (0%)
Head and neck cancer 4/25 (16%) 0/25 (0%)
Esophageal cancer 1/10 (10%) 0/10 (0%)
Kidney cancer 2/20 (10%) 0/20 (0%)
Ovarian cancer 1/11 (9%) 1/11 (9%)
Lymphoma 2/27 (7%) 3/27 (11%)
Breast cancer 1/31 (3%) 1/31 (3%)
Leukemia 0/22 (0%) 4/22 (18%)
Pancreatic cancer 0/8 (0%) 0/8 (0%)
Prostate cancer 0/16 (0%) 1/16 (6%)
The publicly avalilable Oncomine cancer microarray database (accessed in
April 2013) was queried to systematically assess USP1 expression levels across
different cancer types versus the corresponding normal tissue (Analysis type:
Cancer vs Normal). In the “Gene summary view” page, the following
thresholds were set: P-value < 0.05; Fold-change > 1.5; Gene-rank, Top 10%. As
“Data-type”, mRNA was selected. For each cancer type, the number of analyses
that met the thresholds for overexpression or underexpression was recorded,
and is shown in the Table as a ratio (and percentage) with respect to the total
number of analyses in the database.
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USP1 (residues 141-159) has been shown to function as
a nuclear export signal (NES) when tested in a nuclear
export assay [78]. However, the functional relevance of
this motif in the context of full-length USP1 remains to
be established.
The USP1-binding region in UAF1 is relatively large,
and includes its eight predicted WD40 repeats [58].
The identity of the UAF1-binding region in USP1, on
the other hand, is still a matter of some controversy
(Figure 2). By using a cellular relocation assay and co-
immunoprecipitation with GFP-tagged USP1, the UAF1-
binding site was reported to comprise USP1 region
420-520 [73]. In contrast, by using pull-down assays with
bacterially expressed GST-tagged proteins, the UAF1-
binding site was mapped to USP1 region 235-408 [74]. It
is still unclear which one of these USP1 motifs mediates
UAF1 binding, and it remains also possible that more than
one amino acid segment in USP1 contribute to the inter-
action with UAF1. Further experiments and, eventually,
the solution of USP1 three-dimensional structure should
clarify this issue.
Besides the cell cycle-dependent expression of USP1
described above, there are mechanisms that facilitate in-
ducible changes in the levels and activity of USP1 in re-
sponse to genotoxic insults, as expected from its DNA
damage-related functions. Activation of the FA or TLS
pathways would require down-regulation of USP1 to pre-
vent deubiquitination of FANCD2/FANCI and PCNA. In
this regard, transcription of USP1 gene is halted after
DNA damage [58], by a mechanism involving the p21
cyclin-dependent kinase inhibitor [79]. On the other hand,
USP1 protein levels are downregulated in cells exposed to
genotoxic agents, such as UV, by a mechanism that in-
volves autocleavage at an internal diglycine motif
(Gly670-Gly671) (Figure 2) [56]. USP1 autocleavage re-
sults in the generation of an amino-terminal fragment
(USP1NT) and a shorter carboxy-terminal fragment
(USP1CT). Autocleaved USP1 remains enzymatically
active [58] and thus, effective USP1 downregulation re-
quires subsequent proteasomal degradation of the frag-
ments [56] that, in the case of USP1CT, is mediated by
the N-end rule pathway [80].
The observation that autocleaved USP1 remains active
was unexpected, since the cleavage event disrupts its His
box catalytic motif. In this regard, it has been proposed
that USP1NT and USP1CT fragments may be held to-
gether by UAF1 forming a catalytically competent tern-
ary complex [58]. This model, however, seems difficult
to reconcile with the finding that the carboxy-terminal
region of USP1 is unable to interact with UAF1 [73],
and would require further experimental validation.
In contrast to the irreversible destruction of USP1 trig-
gered by UV exposure, reactive oxigen species (ROS)have recently been shown to induce a reversible inacti-
vation of USP1 and also of other cysteine protease
DUBs [81-83]. Mechanistically, inactivation of DUBs by
ROS results from the oxidation of their catalytic cyst-
eine residue, and the sensitivity of these enzymes to
oxidative inhibition is associated with their activation,
which, in the case of USP1, requires its interaction with
UAF1 [81,82]. These findings uncover a novel role for
DUBs as mediators of the cellular response to oxidative
stress. In particular, ROS-mediated regulation of USP1/
UAF1 activity would contribute to modulate the level of
PCNA monoubiquitination in response to oxidative
stress [81,82].
Another reversible modification of USP1 is phosphor-
ylation at Ser313 by cyclin-dependent kinases (CDKs)
[84]. Two functional consequences of Ser313 phosphoryl-
ation have been reported. On one hand, phosphorylation
of this residue, which is located within USP1 degron motif
(Figure 2), may contribute to regulate the cell-cycle
dependent levels of USP1, by preventing its degradation in
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Ser313 has been reported to be necessary for USP1 inter-
action with UAF1 in an in vitro experimental setting [74],
thus raising the possibility that Ser313 phosphorylation
could be a critical regulatory event for USP1 enzymatic ac-
tivity, although these findings await further confirmation
in a more physiological setting.
USP1 alteration in cancer
Mutational alteration of human DUBs, including USP1,
does not appear to be a frequent event in cancer [30].
With the exception of CYLD, mutated in the familial
cylindromatosis syndrome [85], and BAP1, mutated in
several malignancies [86], no other DUBs have been
reported to be recurrently mutated in specific tumor
types. Nevertheless, whole genome analysis of cancer
samples is uncovering low-frequency DUB mutations in
human tumors. In the case of USP1, a survey of the COS-


























































Figure 4 Growth inhibition curves and median-drug effect plots of tw
simultaneous combination. Exponentially growing SW1573 (A) and H129
after seeding, cells were treated with cisplatin, pimozide or a combination
B (SRB) chemosensitivity assay [97] was performed. Briefly, cells were fixed
dry and stained with SRB dye. After washing with 1% acetic acid, cells were
solution. OD at 492 nm was determined. Growth inhibition curves (upper p
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the interaction between cisplatin and pimozide we used the median-drug
Using CalcuSyn, the effect of the combination was compared to the effect
Fa (fraction affected by the dose) values. The resulting C.I. values were plot
cell line (lower panels).synonymous mutations in different tumor types. Thirteen
of these mutations have been detected in lung cancer sam-
ples. Figure 3A shows the distribution of these lung
cancer-associated mutations on USP1 protein. Most of
these are missense mutations, resulting in amino acid sub-
stitutions, but the functional consequences of these pro-
tein changes remain to be established.
Contrasting with the low prevalence of DUB gene mu-
tations, altered mRNA expression of human DUBs is a
recurrent finding in cancer [30,89]. In this regard, a sur-
vey of publically available cancer microarray expression
data using the Oncomine Research Edition database [90]
reveals that USP1 mRNA expression has been found to
be significantly altered (Fold change > 1.5; P-value < 0.05)
in several tumor types (Table 2). Aberrant overexpression
is the most common finding, and it appears to be particu-
larly frequent in cervical and gastric cancer, melanoma
and sarcoma, four tumor types where USP1 results
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9 (B) NSCLC cells were seeded in 96-well plates. Twenty four hours
of both drugs. After 72 hours of drug exposure, the sulforhodamine
with ice-cold trichloroacetic acid, washed with deionized water, left to
left to dry, and protein-bound dye was dissolved in 10 mM Tris base
anels) were generated, where each point represents mean ± SEM of at
rowth by 50% (summarized in Table 3), were calculated by fitting the
nt with the two drugs in combination was carried out using a
lished for each cell line as the ratio of the IC50 values for each single
s for the combination treatment refer to cisplatin. In order to evaluate
effect analysis method originally described by Chou and Talalay [95].
of each drug to determine the combination index (C.I.) at a range of
ted against the Fa to produce the median-drug effect plot for each
Table 3 Effect of the combination between the USP1/
UAF1 inhibitor pimozide with the chemotherapy agent
cisplatin in a panel of NSCLC cell lines
Cell line Cisplatin Pimozide Ratio
C:P
C.I. Combination
effectIC50 (μM) IC50 (μM)
H322 (s) 1.6 11.6 1:7 1.3 Antagonistic
SKLU-1 (s) 2.4 13.7 1:6 1.2 Antagonistic
SW1573 (s) 4.4 10.5 1:2 2.0 Antagonistic
H522 (s) 5.0 10.8 1:2 0.9 Additive
H1299 (r) 7.5 7.0 1:1 0.6 Synergistic
H1703 (r) 8.8 5.0 2:1 1.0 Additive
H520 (r) 13.7 8.7 2:1 1.1 Additive
The IC50 value for cisplatin and pimozide was calculated for each cell line as
described in Figure 4. Cell lines were classified as “cisplatin-sensitive” (s) if
their IC50 for this drug was below the mean value of the panel (6.2 μM), or as
“cisplatin-resistant” (r) if their IC50 was above the mean. Treatment with the
two drugs in combination was carried out using a constant ratio cisplatin:
pimozide (Ratio C:P) that was individually established for each cell line as the
ratio of the IC50 values for each single drug. The combination index (C.I) value
was calculated at a full range of Fa values using CalcuSyn, as described in
Figure 4. We calculated the final C.I. value for each experiment as the average
C.I. at Fa = 0.5, 0.75 and 0.9. At least three independent experiments per cell
line were carried out, and the C.I. value indicated in the Table represents the
mean of the final C.I. values of these experiments. According to the C.I., the
nature of the interaction between the drugs (Combination effect) was
classified as synergistic (C.I. < 0.8), additive (0.8 < C.I. < 1.2) or antagonistic
(C.I. > 1.2).
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osteosarcoma samples demonstrated aberrantly high levels
of both USP1 mRNA and protein, which correlated with
increased expression of its substrate ID2 [57].
Current data on USP1 expression in lung cancer are
somewhat controversial. USP1 overexpression (Fold
change > 1.5; P-value < 0.05) was reported in 25% (4/16) of
the lung cancer microarray sets available through
Oncomine, whereas none of these studies reported signifi-
cant downregulation of USP1. In line with these findings,
USP1 protein overexpression has been found by immuno-
histochemical analysis on a NSCLC tissue microarray
containing 90 paired samples [91]. In contrast, a study
using quantitative RT-PCR and western blot analysis
reported down-regulation of USP1 mRNA and protein in
NSCLC with respect to adjacent tissue [92]. In an attempt
to further clarify this issue, we used quantitative RT-PCR
to analyze USP1 mRNA levels in paired normal/tumor tis-
sue samples from four NSCLC patients (Figure 3B). We
also compared USP1 expression in normal lung tissue
versus three pooled mRNA samples of different NSCLC
histological subtypes (adenocarcinoma, squamous cell
carcinoma and large cell carcinoma), each including five
individual patients (Figure 3C). Finally, we measured
USP1 mRNA levels in a panel of 20 NSCLC cell lines
(Figure 3D). In all these settings, USP1 expression was
higher in tumors or tumor-derived cells than in normal
samples, supporting the association of USP1 over-
expression with NSCLC.
Emerging potential of USP1 as a novel target in NSCLC
Many commonly used chemotherapeutic drugs induce
DNA damage, and chemoresistance may arise if cancer
cells acquire an increased ability to repair or tolerate DNA
lesions [93]. The important regulatory role of USP1 in
DNA repair, supported by the finding that USP1 gene
knockout in model systems leads to DNA damage hyper-
sensitivity [62-64], together with the observation that
USP1 is frequently overexpressed in tumors, suggests that
USP1 could be a relevant target for cancer therapy, whose
inhibition might contribute to overcome chemoresistance.
This view has recently gained experimental support
with the identification of two compounds that inhibit
the activity of the USP1/UAF1 complex, and reverse the
resistance of NSCLC cells to cisplatin [94], a DNA dam-
aging drug commonly used in cancer chemotherapy. In
this study, a high-throughput screening of nearly 10,000
bioactive small-molecules, followed by further validation
and characterization of the best candidates, led to the
identification of two potent and highly selective revers-
ible inhibitors of the enzymatic activity of the USP1/
UAF1 complex, pimozide and GW7647. These inhibitors
were subsequently tested in two NSCLC cell lines to
evaluate their cytotoxic activity in combination withcisplatin. Using cell viability assays and determination of
the combination index (C.I.) [95,96], pimozide and
GW7647 showed synergistic activity with cisplatin in a
cisplatin-resistant NSCLC cell line (H596), but not in a
cisplatin-sensitive cell line (H460).
In an attempt to extend these findings to a larger
number of NSCLC cell lines, we tested the effect of
pimozide in combination with cisplatin on a panel of
seven NSCLC cell lines. A cell viability assay was used to
determine the cytotoxic activity of cisplatin, pimozide or
a combination of both agents. Figure 4 shows represen-
tative examples of the results of this assay in two
NSCLC cell lines, and the data for the remaining cell
lines analyzed are shown in Additional file 2: Figure S1.
The C.I. was subsequently calculated using Calcusyn.
The cell lines tested displayed a wide range of cisplatin
sensitivity, as summarized in Table 3, and were classified
as “ciplatin-sensitive” if their IC50 was below the mean
IC50 of the panel (6.2 μM), or as “cisplatin-resistant” if
their IC50 was above the mean. Pimozide showed a syn-
ergistic or additive effect with cisplatin in the three “re-
sistant” cell lines (H1299, H1703 and H520). In contrast,
the effect of the pimozide/cisplatin combination was
antagonistic in three of the four “sensitive” cell lines
(H322, SKLU-1 and SW1573). These findings are con-
sistent with those of Chen et al. [94], and suggest that
USP1 inhibition may contribute to revert cisplatin resist-
ance in some preclinical models of NSCLC.
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Although significant advances have been made in recent
years, more work is required to achieve a better under-
standing of the basic mechanisms of USP1 function and
regulation. Characterizing the full set of protein-protein
interactions involving USP1 (the “USP1 interactome”)
would be a significant step in this direction. In this
regard, a comprehensive proteomic analysis [98] has
identified a set of 23 novel high confidence candidate
USP1-interacting proteins. Besides UAF1, this set in-
cludes, among others, three other DUBs of the USP
family (USP3, USP4 and USP11) and the phosphatase
PHLPP. The findings of this global study provide a
starting point for more detailed investigations of each
specific interaction, which may lead to the identification
of novel substrates and regulators of USP1.
Regarding its potential as a target for cancer therapy,
the inhibition of USP1 as a strategy to modulate the
efficacy of cisplatin and other DNA damaging drugs
warrants further investigation. For example, the cellular
factors that determine the effect of the combination of
USP1 inhibitors with cisplatin need to be elucidated. On
the other hand, the recent finding that USP1 contributes
to block differentiation in osteosarcoma [57] raises the
possibility that USP1 inhibition could be explored as a
strategy for differentiation therapy in this tumor type.
Besides inhibiting its enzymatic activity, an alternative
approach to target USP1 could be interfering with the
formation of the USP1/UAF1 complex, which is not
disrupted by pimozide and GW7647 [94]. In this regard,
a relocation-based assay for USP1/UAF1 binding, which
could be used to screen for compounds that disrupt
their interaction, has been recently described [73]. This
approach would greatly benefit from a knowledge of the
three-dimensional structure of the USP1/UAF1 complex,
and from a clarification of the controversy regarding the
USP1 region that mediates UAF1 binding [73,74].Additional files
Additional file 1: Table S1. Involvement of selected DUBs in the
regulation of cancer-related signalling pathways and cellular processes.
Table shows several shuman DUBs involved in the regulation of different
signalling pathways/processes, as well as their reported substrates.
Additional file 2: Figure S1. Growth inhibition curves and the
corresponding median-drug effect plots of five NSCLC cell lines treated
with cisplatin, pimozide or their simultaneous combination. Exponentially
growing NSCLC cells were treated and processed as described in
Figure 4. Growth inhibition curves (left panels) were generated, where
each point represents mean ± SEM of at least 3 replicates. IC50 values,
the drug concentration that inhibits the cell growth by 50% (summarized
in Table 3), were calculated by fitting the data to a sigmoid dose–
response curve using GraphPad Prism. The treatment with the two drugs
in combination was carried out using a constant ratio cisplatin:pimozide
(as indicated in Table 3), which was established for each cell line as the
ratio of the IC50 values for each single drug. The drug concentrations on
the X-axis of the growth inhibition curves for the combination treatmentrefer to cisplatin. In order to evaluate the interaction between cisplatin
and pimozide we used the median-drug effect analysis method originally
described by Chou and Talalay. Using CalcuSyn software, the effect of the
combination was compared to the effect of each drug to determine the
combination index (C.I.) at a range of Fa (fraction affected by the dose)
values. The resulting C.I. values were plotted against the Fa to produce
the median-drug effect plot for each cell line (right panels).
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